| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.09 | 0.003 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.003 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.14 | 0.005 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |